The diabetic patients in the country have good news which can save their monthly medicine bills. Over 15-20 companies are launching generic versions of the widely-prescribed anti-diabetic drug Vildagliptin, with its price expected to crash by half. The potential of more affordable diabetic care came in the wake of Swiss major Novartis-owned Vildagliptin losing patent […]